Dapagliflozin significantly shortened the time to clinical benefit in patients with heart failure with reduced ejection fraction compared to those with prior hospitalization for heart failure.
Absolute Event Rate: 0% vs 0%
ClinicalTrials.gov Identifier NCT03036124.
Berg et al. (Sat,) reported a other. Dapagliflozin significantly shortened the time to clinical benefit in patients with heart failure with reduced ejection fraction compared to those with prior hospitalization for heart failure.